Allergan, Inc.

Allergan, Inc. is a U.S. pharmaceutical company founded in 1948 by pharmacist Gavin S. Herbert (incorporated 1950) and headquartered at 2525 Dupont Drive, Irvine, California. It went public in 1970 and traded as NYSE: AGN until Actavis plc acquired it in 2015 and adopted the Allergan name (Allergan plc, Dublin-domiciled). AbbVie Inc. (NYSE: ABBV) completed its acquisition of Allergan plc on May 8, 2020; Allergan, Inc. survives as an indirect, wholly owned subsidiary of AbbVie, a fact Allergan itself stated in a 2019 Supreme Court filing. Historical scale: roughly 11,000 employees and ~$5.8B revenue in FY2013 (Contract Pharma). AbbVie reported $10.3B of net revenues attributable to Allergan for the period from the May 2020 acquisition date through December 31, 2020.

It is an operating company, not a non-practicing entity. Its historic franchises span eye care (e.g., Restasis, Lumigan, Alphagan), medical aesthetics (Botox Cosmetic, Juvéderm, CoolSculpting), neurosciences (Botox Therapeutics, Vraylar, Ubrelvy), medical dermatology, urologics, and breast/obesity-related devices (Natrelle, Lap-Band). Post-acquisition, these sit within AbbVie's neuroscience and "Allergan Aesthetics" businesses.

Patent-litigation posture: operating company and net patent plaintiff. The tracked data show 1 case as plaintiff and 0 as defendant, all in the U.S. District Court for the District of Delaware — the standard venue for branded-drug Hatch-Waxman litigation, not a plaintiff-friendly NPE forum like the Eastern District of Texas. Allergan has historically been a frequent pharmaceutical patent enforcer rather than a target of NPE suits.

Tracked case: Allergan, Inc. v. Pharmacia Corp., No. 1:01-cv-00141 (D. Del., Judge Robinson), a dispute involving two patents covering glaucoma drugs; Allergan was represented by Finnegan. Docket records show Allergan Inc. and Allergan Sales, Inc. as plaintiffs against Pharmacia Corporation, Pharmacia AB, Pharmacia Enterprises S.A. and Pharmacia & Upjohn Company. External context: Allergan's better-known patent disputes include the Restasis inter partes review and Saint Regis Mohawk Tribe sovereign-immunity assignment (E.D. Tex./Fed. Cir.) and the eluxadoline/Viberzi obviousness-type double patenting appeals.